# | Reference | Setting | Target population | Type of analysis | Perspective | Intervention type | Comparator | Model type | Time horizon |
---|---|---|---|---|---|---|---|---|---|
1 | Agartioglu (2020) [50] | Turkey, Izmir | CD adults aged 65+ | CEA | Public sector | HAM | UC | DT | 1 year |
2 | Albert (2016) [51] | US, Pennsylvania | CD adults aged 50+ (mean age 75.5) | CUA | Public sector | MF int. | UC | DT | 1 year |
3 | Alhambra-Borras (2019) [52] | Spain, Valencia, hospital level | CD adults aged 65+ at high falls risk or frail with no severe physical or cognitive limitation | CUA | Public sector | Exercise | UC | Markov cohorta | Lifetime |
4 | Beard (2006) [53] | Australia, NSW | CD adults aged 60+ | CBA; ROI | Public sector; Societal | MC (intersectoral) int.b | UC | Binary decisionc | 5 years |
5 | Boyd (2020) [54] | New Zealand | Adults aged 65+ | CUA | Public sector | Cataract surgery (expedited, routine) | NR | Markov cohort | Lifetime |
6 | Carande-Kulis (2015) [55] | US, private insurers | CD adults aged 65+ | ROI | US health insurance payer | Exercise (2 forms); MC int. (Stepping On) | NR | Binary decision | 1 year |
7 | CSP (2016) [56] | UK, varying regions | CD adults aged 65+ | ROI | Public sector | FRS + Exercise (physiotherapy) | NR | DT | 1 year |
8 | Church (2011) [57] | Australia, NSW | CD adults aged 65+ (separate model for residential care) | CEA; CUA | Public sector | Exercise (3 forms); MC int.; MF int.; MRA; Exp. cataract surgery; Med. modification; Cardiac pacing | NR | Markov cohort | 10 years |
9 | Church (2012) [58] | Australia, NSW | CD adults aged 65+ | CEA; CUA | Public sector | Exercise (4 forms); MC int.; MF int. (2 forms); MRA; HAM; Exp. cataract surgery; Cardiac pacing; Med. modification | NR; Cross-comparison | Markov cohort | Lifetime |
10 | Comans (2009) [59] | Australia, Brisbane | CD adults aged 65+, falls history in past 6 months or gait/functional decline and cognitively intact | ROI | Societal | MF int. (2 forms) | NR | Binary decision | 1 year |
11 | Day (2009) [60] | Australia, varying regions | CD adults aged 50+ (age and characteristics differ by intervention type)d | CEA | Public sector; Societal | Exercise (2 forms); HAM; MF int.; Med. modification; Cardiac pacing | NR | DT | 1 year |
12 | Day (2010) [61] | Australia | CD adults aged 70+ | CEA | Public sector; Societal | Exercise (Tai Chi) | NR | DT | 1 year |
13 | Deverall (2018) [62] | New Zealand | CD adults aged 65+ | CUA | Public sector; Societal | Exercise (3 forms) | NR | Markov cohort | 25 years |
14 | Eldridge (2005) [63] | UK, primary care trust | Adults aged 65+ in community or nursing home | CUA | Public sector | FRS + MF int. or Exercise | UC | DT + Markov cohort | Lifetime |
15 | Farag (2015) [64] | Australia | CD adults aged 65+ without falls history | CUA | Public sector | Non-specific intervention | NR | Markov cohort | Lifetime |
16 | Franklin (2019) [65] | UK, city level | CD adults aged 65+ | CUA | Public sector (2 types) | FRS + Exercise (3 forms) or HAM | NR; Cross-comparison | DT + Markov cohort | 2 years |
17 | Frick (2010) [66] | US | CD adults aged 65+ | CUA | US healthcare payere | Exercise (2 forms); HAM; MF int. (2 forms); Vit. D; Med. modification | Cross-comparison | Binary decision | 1 yearf |
18 | Hektoen (2009) [67] | Norway | CD women aged 80+ | CEA | Societal | Exercise | NR | Binary decision | 1 year |
19 | Hiligsmann (2014) [68] | Belgium | Adults aged 60+ with osteoporosis | CUA | Societal | Vit. D and calcium | NR | Markov patienta | Lifetime |
20 | Hirst (2016) [69] | UK | Women aged 75+ on chronic pain medication | CUA | Public sector | Med. modification (Transdermal Buprenorphine) | Tramadol | DTg | 1 year |
21 | Honkanen (2006) [70] | US, Medicare/aid | Adults aged 65+ living in community at baseline | CUA; ROI | Societal | Hip protectors | NR | Markov cohort | Lifetime |
22 | Howland (2015) [71] | US, Massachusetts | CD adults aged 65+ admitted to A&E due to fall | ROI | US healthcare payere | MC int. (MoB/VLL) | NR | Binary decision | 1 year |
23 | Ippoliti (2018) [72] | Italy, Piedmont | CD adults aged 65+ living in mountainous areas | ROI | Public sector | MF int. | NR | Binary decision | 3 years |
24 | Johansson (2008) [73] | Sweden, Stockholm | CD adults aged 65+ | CUA | Societal | MC (intersectoral) int.h | UC | Markov cohort | Lifetime |
25 | Lee (2013) [74] | US, Medicare/aid | CD adults aged 65–80 without falls history | CBA | Public sector | Vit. D (targeted, universal) | NR | DT + Markov cohort | 3 years |
26 | Ling (2008) [75] | US, Hawaii | CD adults aged 65+ with falls history or other risk factors | ROI | US healthcare payere | HAM | NR | Binary decision | 1 year |
27 | McLean (2015) [76] | Australia, Melbourne | CD adults aged 70+ | CEA; CUA | Public sector | Exercise | UC | DT | 18 months |
28 | Miller (2011) [77] | US, Texas | CD adults aged 50+ at high falls risk | ROI | US healthcare;e Societal | MC int. (MoB/VLL) | NR | Binary decision | 2 years |
29 | Mori (2017) [78] | US | CD women aged 65+ at osteoporosis risk without previous fracture | CUA | Societal | Exercise and bisphosphonate combined | Cross-comparison: single or no intervention | DT + Markov patient | Lifetime |
30 | Moriarty (2019) [79] | Ireland | CD adults aged 65, no current/previous adverse events for benzodiazepine/PPI | CUA | Public sector | Med. modification (Benzodiazepine, PPIn) | Inappropriate prescribing | DT + Markov patient | 35 years |
31 | Nshimyu-mukiza (2013) [80] | Canada | Women aged 40+ (with subgroup aged 65+) | CEA; CUA | Public sector | Fracture risk screening + Physical activity, Vit. D and calcium, and/or Osteoporosis screen & treat | NR; Cross-comparison | DT + Markov patient | Lifetime |
32 | OMAS (2008) [81] | Canada, Ontario | CD adults aged 65+ | CEA; ROI | Public sector | Exercise; HAM; Vit. D and calcium; Med. modification; gait-stabilizer | NR | Markov cohort | Lifetime |
33 | Pega (2016) [82] | New Zealand | CD adults aged 65+ | CUA | Public sector | HAM | NR | Markov cohort | Lifetime |
34 | Poole (2014) [83] | UK | Adults aged 65+ | ROI | Public sector | Vit. D | NR | Binary decision | 1 year |
35 | Poole (2015) [84] | UK | CD adults aged 60+ | CUA; ROI | Public sector | Vit. D | NR | Markov cohort | 5 years |
36 | PHE (2018) [85] | England, varying regions | CD adults aged 65+ | CUA; ROI | Public sector | Exercise (3 forms); HAM | NR | DT | 2 years |
37 | RCN (2005) [34] | England & Wales | CD adults aged 60+ | CUA | Public sector | Exercise; MF int. | NR | Markov cohort | Lifetime |
38 | Sach (2007) [86] | UK | Women aged 70+ with bilateral cataracts | CEA; CUA | Public sector; Societal | Exp. cataract surgery (first eye) | UC (routine surgery) | Binary decision | Lifetime extrapol.i |
39 | Sach (2010) [87] | UK | Women aged 70+ with second operable cataract | CUA | Public sector; Societal | Exp. cataract surgery (second eye) | UC (no surgery) | Binary decision | Lifetime extrapol.i |
40 | Smith (2016) [88] | UK, NW London | Adults aged 65+ covered by GP practice and hospital | ROI | Public sector | FRS + MF int. | Cross-comparison | Risk prediction | 1 year |
41 | Tannenbaum (2015) [89] | US, Medicare/aid | CD adults aged 65+ with insomnia | CUA | Public sector | Med. modification; CBT | NR; Cross-comparison | Markov cohort | 1 year |
42 | Turner (2020) [90] | Canada, Quebec | CD adults aged 65+ who are chronic users of sedatives for insomnia | CUA | Public sector | Med. modification | NR | DT + Markov cohort | 1 year |
43 | Velde (2008) [91] | Netherlands | CD geriatric outpatient population with falls history (mean age 78) | CEA | Public sector | Med. modification | NR | Binary decision | 1 yearf |
44 | Wilson (2017) [92] | New Zealand, Manukau | CD adults aged 65+ | CUA | Public sector | HAM | NR | Markov cohort | Lifetime |
45 | Wu (2010) [93] | US, Medicare/aid | CD Medicare beneficiaries aged 65+ with falls history | CEA; ROI | Public sector; Societal | MF int. | NR | Binary decision | 1 year |
46 | Zarca (2014) [94] | France | Adults aged 65+ without previous hip fracture | CEA; CUA | Public sector | Vit. D (targeted (2), universal) | NR; Cross-comparison | DT + Markov patient | Lifetime |